MARIETTA, Ga., June 29, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that its Chairman and CEO, Parker H. "Pete" Petit, has been awarded the Lifetime Achievement Award in the EY Entrepreneur Of The Year® 2015 Southeast Program.
The Entrepreneur Of The Year Program, now in its 29th year, has expanded globally to recognize company builders in over 145 cities and in more than 60 countries worldwide. The program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their business and communities. The regional award recipients go on to compete for the EY Entrepreneur Of The Year National Awards which will be announced at the EY Strategic Growth Forum®, the nation's most prestigious gathering of high-growth, market-leading companies.
In addition to Pete Petit, ten other entrepreneurs were named award recipients in various industry categories in the Southeast Program. EY acknowledged Petit for his success as a serial entrepreneur, and for leading and investing personally in MiMedx at a time when the company had no revenue.
Petit said, "I am truly honored to receive this Lifetime Achievement Award. I am proud to be in the same company as the ten other award recipients in this year's Entrepreneur Of The Year Southeast Program. My successes have all been team efforts, and I share this award with the many talented individuals that I have been blessed to have as my teammates at our several organizations."
EY is the global leader in assurance, tax, transaction and advisory services. The insights and quality services they deliver help build trust and confidence in the capital markets and in economies the world over. EY develops outstanding leaders who team to deliver on its promises to all of its stakeholders. In doing so, EY plays a critical role in building a better working world for its people, for its clients and for its communities.
EY refers to the global organization and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about the organization, please visit ey.com.
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 400,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
SOURCE MiMedx Group, Inc.